221 related articles for article (PubMed ID: 16229894)
1. Therapeutic role of beta-interferons in multiple sclerosis.
Javed A; Reder AT
Pharmacol Ther; 2006 Apr; 110(1):35-56. PubMed ID: 16229894
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
3. Biologic effects of interferons: relevance to multiple sclerosis.
Rudick RA; Ransohoff RM
Mult Scler; 1995; 1 Suppl 1():S12-6. PubMed ID: 9345391
[TBL] [Abstract][Full Text] [Related]
4. Interferons in multiple sclerosis: ten years' experience.
Tourbah A; Lyon-Caen O
Biochimie; 2007; 89(6-7):899-902. PubMed ID: 17574320
[TBL] [Abstract][Full Text] [Related]
5. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
[TBL] [Abstract][Full Text] [Related]
6. Role of the interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune disorders.
Mondini M; Vidali M; Airò P; De Andrea M; Riboldi P; Meroni PL; Gariglio M; Landolfo S
Ann N Y Acad Sci; 2007 Sep; 1110():47-56. PubMed ID: 17911419
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
8. Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis.
Petersen T; Møller-Larsen A; Thiel S; Brudek T; Hansen TK; Christensen T
J Neuroimmunol; 2009 Oct; 215(1-2):108-16. PubMed ID: 19766328
[TBL] [Abstract][Full Text] [Related]
9. Interferons in multiple sclerosis. A review of the evidence.
Panitch HS
Drugs; 1992 Dec; 44(6):946-62. PubMed ID: 1282865
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1.
Sanna A; Huang YM; Arru G; Fois ML; Link H; Rosati G; Sotgiu S
Mult Scler; 2008 Nov; 14(9):1199-207. PubMed ID: 18653740
[TBL] [Abstract][Full Text] [Related]
11. Interference by interferons: Janus faces in vascular proliferative diseases.
Wessely R
Cardiovasc Res; 2005 Jun; 66(3):433-43. PubMed ID: 15914108
[TBL] [Abstract][Full Text] [Related]
12. Infections and autoimmune diseases.
Bach JF
J Autoimmun; 2005; 25 Suppl():74-80. PubMed ID: 16278064
[TBL] [Abstract][Full Text] [Related]
13. Type I interferon therapy and its role in autoimmunity.
Biggioggero M; Gabbriellini L; Meroni PL
Autoimmunity; 2010 Apr; 43(3):248-54. PubMed ID: 20298125
[TBL] [Abstract][Full Text] [Related]
14. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation.
Zozulya AL; Wiendl H
Hum Immunol; 2008 Nov; 69(11):797-804. PubMed ID: 18723060
[TBL] [Abstract][Full Text] [Related]
15. Type I interferon response in the central nervous system.
Paul S; Ricour C; Sommereyns C; Sorgeloos F; Michiels T
Biochimie; 2007; 89(6-7):770-8. PubMed ID: 17408841
[TBL] [Abstract][Full Text] [Related]
16. The impact of interferon-beta treatment on the blood-brain barrier.
Kraus J; Oschmann P
Drug Discov Today; 2006 Aug; 11(15-16):755-62. PubMed ID: 16846804
[TBL] [Abstract][Full Text] [Related]
17. Immunopathogenesis and immunotherapy of multiple sclerosis.
Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.
Antel JP; Miron VE
Clin Neurol Neurosurg; 2008 Nov; 110(9):951-7. PubMed ID: 18502570
[TBL] [Abstract][Full Text] [Related]
19. Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides?
Staines DR
Med Hypotheses; 2008; 70(2):413-8. PubMed ID: 17582695
[TBL] [Abstract][Full Text] [Related]
20. New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS.
Prinz M; Kalinke U
Trends Mol Med; 2010 Aug; 16(8):379-86. PubMed ID: 20591737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
